# Bradford C. Webb, PhD

> Bradford C. Webb, PhD is a Series B investor at Claremont Creek Ventures backing Biotechnology. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Claremont Creek Ventures](https://shizune.co/investors/profile/claremont-creek-ventures)
- Location: San Francisco Bay Area, United States
- Total investments: 4
- Last investment: Aug 2015
- Lead investor: 75%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/brad-webb-6b54742a

Bradford C. Webb, PhD is a Series B investor at Claremont Creek Ventures in San Francisco Bay Area focused on Biotechnology and Health Care. Brad Webb is an experienced entrepreneur and investor in the biomedical and biotech industries. In addition to his active role as a Venture Partner at Claremont Creek, Brad consults with other venture firms specializing in medical and pharmaceutical early-stage investing.After receiving a PhD in Biochemistry and Molecular Biology from theUniversity of California at Santa Barbara in 1979, Brad joined 3M Company's ophthalmology products division as a research and development scientist working on designs for post-cataract surgery intraocular lenses. He also supervised human clinical trials and FDA approval processes for 3M. After leaving 3M, Brad led or participated in several start-up ventures in the ophthalmic products industry, with responsibility for research, clinical trials and FDA affairs.In 1988 Brad founded Vision Biology, Inc., to develop new viscoelastic products for use in eye surgery. Vision Biology's revolutionary patented Viscoelastic Surgical Fluid for use during cataract surgery was licensed to Alcon Laboratories in 1996. Brad spent several years consulting for Alcon on a variety of medical product research and development projects, and recently has participated in investments in biotech and medical technology companies.Brad is a member of Tech Coast Angels, a Southern California based Angel group, is active with UC Santa Barbara technology programs, and will be instrumental in extending the reach of Claremont Creek into the broader Southern California technology region.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 75% |
| Health Care | 2 | 50% |
| Medical | 1 | 25% |
| Genetics | 1 | 25% |
| Hospital | 1 | 25% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 50% |
| Series C | 2 | 50% |
| Series A | 1 | 25% |
| Series D | 1 | 25% |
| Debt Financing | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Genalyte | Genalyte, Inc. is a life sciences company developing and commercializing innovative next-generation multiplexing technology. Genalyte has developed a new approach to immunodetection using silicon chip manufacturing methods. Its Maverick platform uses a technology called silicon photonics to directly measure protein binding between antibodies andantigens or hybridization of nucleic acids. | $44M | Series C | Aug 18, 2015 |  |
| Assurerx Health | Assurex Health is a personalized medicine company dedicated to helping clinicians determine the right medication for individual patients with medical conditions. Assurex Health’s proprietary Genesight® technology is based on pharmacogenomics – the study of the genetic factors that influence an individual’s response to drug treatments – as well asevidence-based medicine and clinical pharmacology. | $12.5M | Series C | May 30, 2012 |  |
| Genalyte | Genalyte, Inc. is a life sciences company developing and commercializing innovative next-generation multiplexing technology. Genalyte has developed a new approach to immunodetection using silicon chip manufacturing methods. Its Maverick platform uses a technology called silicon photonics to directly measure protein binding between antibodies andantigens or hybridization of nucleic acids. | $11.8M | Series B | Mar 30, 2012 |  |
| Assurerx Health | Assurex Health is a personalized medicine company dedicated to helping clinicians determine the right medication for individual patients with medical conditions. Assurex Health’s proprietary Genesight® technology is based on pharmacogenomics – the study of the genetic factors that influence an individual’s response to drug treatments – as well asevidence-based medicine and clinical pharmacology. | $11M | Series B | Mar 25, 2011 |  |

4 of 4 investments shown.

## Co-investors
- [Allos Ventures](https://shizune.co/investors/profile/allos-ventures) — VC Fund, 2 deals together
- [CincyTech](https://shizune.co/investors/profile/cincytech) — VC Fund, 2 deals together
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund, 2 deals together
- [Four Rivers Group](https://shizune.co/investors/profile/four-rivers-group) — VC Fund, 1 deal together
- [Pfeffer Capital](https://shizune.co/investors/profile/pfeffer-capital) — VC Fund, 1 deal together

## About Claremont Creek Ventures

VC Fund · Oakland, United States

Claremont Creek Ventures (CCV) is a seed and early stage venture firm. CCV invests in companies that serve essential, broad-impact industries with innovative digital solutions that increase efficiency or create entirely new high-growth, high-margin businesses. As part of CCV’s investment strategy, the firm practices “life cycle venturing”:establishing in-depth, active relationships with entrepreneurs alongside or even ahead of early-stage funding events. Claremont Creek Ventures has invested in over 40 companies including Clean Power Finance, EcoATM, and Natera and manages more than $300 million across two funds. Visit www.claremontcreek.com.

5 contacts available at Claremont Creek Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Gianna Conci Orozco | Finance Manager | https://shizune.co/investors/profile/gianna-conci-orozco |
| Harveen Sethi | Associate | https://shizune.co/investors/profile/harveen-sethi |
| Nathaniel Goldhaber | Co-Founder & Managing Director | https://shizune.co/investors/profile/nat-goldhaber |
| Randy Hawks | Managing Director | https://shizune.co/investors/profile/randy-hawks |
| Bradford C. Webb, PhD | Venture Partner | https://shizune.co/investors/profile/bradford-c-webb-phd |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Bradford C. Webb, PhD invest in?

Bradford C. Webb, PhD invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series C stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Bradford C. Webb, PhD last invest?

The most recent investment recorded for Bradford C. Webb, PhD closed in Aug 2015. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co